Table 1. Demographic and clinical characteristics of study participants according to tumour molecular type.

TN: Triple-negative.

Variables	Overall (n = 17)	Luminal (n = 9)	HER2 (n = 6)	TN (n = 2)
Sex, n (%)
Female	16 (94)	8 (89)	6 (100)	2 (100)
Male	1 (6)	1 (11)	0 (0)	0 (0)
Age at diagnosis (years), median (range)	50 (26-72)	50 (26-72)	52 (34-64)	50 (47-53)
Race, n (%)
Caucasian	17 (100)	9 (100)	6 (100)	2 (100)
Tumour size, n (%)
≤5 cm (T1 and T2)	10 (59)	5 (56)	4 (67)	1 (50)
>5 cm (T3 and T4)	7 (41)	4 (44)	2 (33)	1 (50)
Nodal involvement, n (%)
N0	4 (24)	3 (33)	1 (17)	0 (0)
N1-N3	13 (76)	6 (67)	5 (83)	2 (100)
Oestrogen receptor, n (%)
Positive ≥1%	11 (65)	9 (100)	2 (33)	0 (0)
Negative <1%	6 (35)	0 (0)	4 (67)	2 (100)
Progesterone receptor, n (%)
Positive ≥1%	10 (59)	8 (89)	2 (33)	0 (0)
Negative <1%	7 (41)	1 (11)	4 (67)	2 (100)
Ki-67 expression, n (%)
High (>20%)	13 (76)	5 (56)	6 (100)	2 (100)
Low (≤20%)	4 (24)	4 (44)	0 (0)	0 (0)
Type of metastatic disease, n (%)
Oligometastatic	12 (71)	7 (78)	3 (50)	2 (100)
Multimetastatic	5 (29)	2 (22)	3 (50)	0 (0)